No Detail Found!

Combination therapy of methotrexate and iguratimod for female patients with moderate to severe active rheumatoid arthritis and its impact on ovarian function

Author(s)
Zhang Jingzhou Chongqing Chemical Industry Vocational College,Chongqing,China
Zhou Xiong Chongqing Chemical Industry Vocational College,Chongqing,China
Kong Qing Xin Chongqing Chemical Industry Vocational College,Chongqing,China
Abstract
Rheumatoid arthritis is systemic inflammatory disease, presenting as symmetrical polyarthritis, mainly affecting hands and feet. Female patients with rheumatoid arthritis have also decreased fertility and premature ovarian failure. Methotrexate is used in treatment of rheumatoid arthritis. However, single treatment of Methotrexate is not ideal and often needs to be combined with other drugs like Iguratimod for intensive treatment of refractory rheumatoid arthritis. We aim to explore efficacy of combined use of MTX and IGU for female patients with rheumatoid arthritis and its impact on ovarian reserve function. Total 80 female patients with moderate to severe active rheumatoid arthritis were selected and randomly divided into MTX and MTX + IGU groups. The MTX + IGU group showed lower levels of IL1ß, IL-6, IL-17, and TNF-a after treatment as compared to MTX group. The MTX + IGU group showed significantly higher level of AMH at the end of treatment. However, no statistical differences were observed in FSH, LH, E2 and AFC levels between the two groups. The combined therapy of MTX and IGU has better efficacy with less impact on ovarian function, even improving ovarian reserve function through effective control of rheumatoid inflammatory activity.
Publication Details
Page(s) 1657-1662
Published Journal: Pakistan Journal of Pharmaceutical Sciences, Volume: 36, Issue: 5-S, Year: 2023

Request the full text from PASTIC

Keywords
Rheumatoid arthritis, inflammation, Methotrexate, Ovarian function, iguratimod
0

Citations

0

Downloads

57

Views